- Email: [email protected]
ECCLU 2011 Invited Speakers' Disclosures
Critical Reviews in Oncology/Hematology 78 S1 (2011) S29
ECCLU 2011 Invited Speakers’ Disclosures Jan J. Battermann: Over the years I worked with several vendors of iodine seeds, including Oncura, Ibt, Nucletron and Best. I helped in the training of new centres in Europe and was invited as speaker on conferences and symposia. Due to the collaboration we were able to compare results with different seeds and used these results for publication in radiotherapy and urology journals. In my opinion there is no bias in the presented materials from our centre. Joaquim Bellmunt: No significant relationships Dominik Berthold: No significant relationships Axel Bex: I have received honoraria from Pfizer, Bayer and Novartis for having attended advisory board meetings Michel Bolla: No significant relationships Cristina Bosetti: No significant relationships Noel Clarke: No significant relationships Zoran Culig: Company sponsored research (CENTOCOR) Johann de Bono: No significant relationships Maria De Santis: Consultancies and advisory board services for Novartis, GSK, Pierre-Fabre Oncology, Roche, Amgen, Bayer, Pfizer, Eli Lilly, Sanofi-Aventis, Janssen Cilag Louis Denis: No significant relationships Vincenzo Ficarra: No significant relationships Karim Fizazi: Honoraria and participation on advisory boards for: Sanofi-Aventis, AstraZeneca and Keocyt Vincent Griesser: No significant relationships Freddie Hamdy: No significant relationships Axel Heidenreich: No significant relationships Alan Horwich: No significant relationships Nicholas James: No significant relationships Fran¸cois J. Murat: No significant relationships Chris Parker: No significant relationships Brian Rini: Consulting fees and research funding from GSK, Pfizer, Genentech/Roche George N. Thalman: No significant relationships Ian Tannock: Received research funding from Sanofi-Aventis (makers of docetaxel and cabaziitaxel) but not in last two years. I have received research funding from Johnson and Johnson in lieu of honoraria for serving as chair of the Data Safety Monitoring Committee for a trial of Abiraterone Acetate. I do not accept personal payments from companies. Bertrand Tombal: Investigator and/or paid advisor for Astellas, Amgen, Ferring, Medivation, Johnson and Johnson, Ferring, Sanofi-Synthelabo St´ephane Supiot: Currently conducting research sponsored by AstraZeneca Catherine Terret: No significant relationships Hendrik Van Poppel: No significant relationships Anders Widmark: No significant relationships Thomas Wiegel: No significant relationships 1040-8428/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
ECCLU 2011 Invited Speakers’ Disclosures Jan J. Battermann: Over the years I worked with several vendors of iodine seeds, including Oncura, Ibt, Nucletron and Best. I helped in the training of new centres in Europe and was invited as speaker on conferences and symposia. Due to the collaboration we were able to compare results with different seeds and used these results for publication in radiotherapy and urology journals. In my opinion there is no bias in the presented materials from our centre. Joaquim Bellmunt: No significant relationships Dominik Berthold: No significant relationships Axel Bex: I have received honoraria from Pfizer, Bayer and Novartis for having attended advisory board meetings Michel Bolla: No significant relationships Cristina Bosetti: No significant relationships Noel Clarke: No significant relationships Zoran Culig: Company sponsored research (CENTOCOR) Johann de Bono: No significant relationships Maria De Santis: Consultancies and advisory board services for Novartis, GSK, Pierre-Fabre Oncology, Roche, Amgen, Bayer, Pfizer, Eli Lilly, Sanofi-Aventis, Janssen Cilag Louis Denis: No significant relationships Vincenzo Ficarra: No significant relationships Karim Fizazi: Honoraria and participation on advisory boards for: Sanofi-Aventis, AstraZeneca and Keocyt Vincent Griesser: No significant relationships Freddie Hamdy: No significant relationships Axel Heidenreich: No significant relationships Alan Horwich: No significant relationships Nicholas James: No significant relationships Fran¸cois J. Murat: No significant relationships Chris Parker: No significant relationships Brian Rini: Consulting fees and research funding from GSK, Pfizer, Genentech/Roche George N. Thalman: No significant relationships Ian Tannock: Received research funding from Sanofi-Aventis (makers of docetaxel and cabaziitaxel) but not in last two years. I have received research funding from Johnson and Johnson in lieu of honoraria for serving as chair of the Data Safety Monitoring Committee for a trial of Abiraterone Acetate. I do not accept personal payments from companies. Bertrand Tombal: Investigator and/or paid advisor for Astellas, Amgen, Ferring, Medivation, Johnson and Johnson, Ferring, Sanofi-Synthelabo St´ephane Supiot: Currently conducting research sponsored by AstraZeneca Catherine Terret: No significant relationships Hendrik Van Poppel: No significant relationships Anders Widmark: No significant relationships Thomas Wiegel: No significant relationships 1040-8428/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.